Published 06/08/2024 7:19:00 p.m.

FDA approves first RSV vaccine for at-risk adults in their 50s

The FDA expanded approval of GSK's RSV vaccine to adults aged 50 to 59 at risk of severe illness.
Arexvy is the first vaccine FDA approved to protect this age group from RSV.
Initially approved for ages 60 and above, GSK's jab's safety data in 50-59 group aligned with older adults.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

Reuters

US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59

The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age group.

06/08/2024 7:19:00 p.m.·United Kingdom

Read Full Article

CNBC

FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach

The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

06/07/2024 10:20:54 p.m.·United States

Read Full Article

CBS News

FDA approves first RSV vaccine for at-risk adults in their 50s

The RSV vaccine by GSK was previously approved only for adults 60 and older.

06/07/2024 11:25:12 p.m.

Read Full Article

The Hill

FDA approves first RSV vaccine for use in at-risk adults over 50

The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker, announced the approval Friday, making it the first vaccine rubber-stamped for adults ages 50-59 to protect against the virus. “Today’s approval reflects the importance…

06/08/2024 2:15:58 p.m.·Washington, United States

Read Full Article

The Straits Times

US FDA expands GSK’s RSV vaccine approval to adults aged 50 to 59

RSV vaccines are approved for those above 60; Arexvy is 1st to be approved for this age group. Read more at straitstimes.com.

06/09/2024 2:50:00 a.m.·Singapore

Read Full Article

UPI

FDA clears GSK's RSV vaccine for adults ages 50-59

The U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the shot's accessibility to younger patients.

06/08/2024 9:14:35 p.m.·Washington, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year